Related Experiment Video
Updated: Jun 22, 2026

A Standardized Pipeline for Examining Human Cerebellar Grey Matter Morphometry using Structural Magnetic Resonance Imaging
Published on: February 4, 2022
MRI measures show significant cerebellar gray matter volume loss in multiple sclerosis and are associated with
V M Anderson1, L K Fisniku, D R Altmann
1Nuclear Magnetic Resonance Research Unit, Institute of Neurology, University College London, Queen Square, London, UK. vanderson@ion.ucl.ac.uk
Background:
Regional atrophy measures may offer useful information about the causes of specific clinical deficits in multiple sclerosis (MS).
Objective:
To determine the magnitude of cerebellar gray and white matter (GM and WM) atrophy in patients with clinically isolated syndromes (CIS) and MS, and their role in clinical manifestations of cerebellar damage.
Methods:
T1-weighted volumetric magnetic resonance imaging (MRI) of 73 patients [29 CIS, 33 relapsing-remitting MS (RRMS), 11 secondary progressive MS (SPMS)] was compared with 25 controls. GM and WM regions were generated using SPM5 and cerebellar regions delineated. Linear regression was used to investigate differences in tissue-specific cerebellar volumes between groups and the association with clinical measures.
Results:
Mean cerebellar GM volume (CGMV) was 100.1 cm(3) in controls, 96.4 cm(3) in CIS patients, 91.8 cm(3) in RRMS patients, and 88.8 cm(3) in SPMS patients. Mean cerebellar WM volumes (CWMV) were 21.3 cm(3), 20.4 cm(3), 19.9 cm(3), and 18.8 cm(3), respectively. CGMV was reduced by 4.8 cm(3) (P = 0.054) in RRMS patients, and 8.5 cm(3) (P = 0.012) in SPMS patients, relative to controls. Only patients with SPMS showed a borderline significant reduction in CWMV compared with controls (mean 2.1 cm(3), P = 0.053). CGMV was significantly smaller in patients assessed as having cerebellar dysfunction compared with patients who had normal cerebellar function. Significant associations of CGMV and CWMV with performance on the nine-hole peg test were also observed.
Conclusion:
Clinically relevant GM atrophy occurs in the cerebellum of MS patients and is more prominent than WM atrophy. As such, it may provide complementary data to other regional atrophy and intrinsic tissue measures.
Insights
Cerebellar gray matter atrophy is evident in multiple sclerosis (MS) patients, particularly in later stages, and correlates with cerebellar dysfunction and motor impairment. This finding highlights the importance of regional atrophy in understanding MS progression.
Area of Science:
- Neuroimaging
- Neurology
- Radiology
Background:
- Regional atrophy measurements can reveal causes of clinical deficits in multiple sclerosis (MS).
- Cerebellar involvement is crucial in understanding MS-related neurological impairments.
Purpose of the Study:
- To quantify cerebellar gray matter (GM) and white matter (WM) atrophy in patients with clinically isolated syndromes (CIS) and MS.
- To assess the relationship between cerebellar atrophy and clinical manifestations of cerebellar damage.
Main Methods:
- Volumetric T1-weighted MRI scans were analyzed for 73 patients (29 CIS, 33 relapsing-remitting MS, 11 secondary progressive MS) and 25 controls.
- Cerebellar GM and WM regions were segmented using SPM5.
- Linear regression examined group differences in cerebellar volumes and associations with clinical measures.
Main Results:
- Significant reductions in cerebellar gray matter volume (CGMV) were observed in relapsing-remitting MS and secondary progressive MS (SPMS) patients compared to controls.
- SPMS patients showed a borderline significant reduction in cerebellar white matter volume (CWMV).
- Reduced CGMV and CWMV correlated with cerebellar dysfunction and impaired performance on the nine-hole peg test.
Conclusions:
- Clinically significant cerebellar gray matter atrophy is present in MS patients, exceeding white matter atrophy.
- Cerebellar atrophy measurements provide valuable complementary data to other regional and tissue-specific measures in MS assessment.
Related Concept Videos
Magnetic Resonance Imaging
Multiple Sclerosis l: Introduction

